Non-natural consensus albumin binding domains

Abstract

Non-natural albumin binding domains, polynucleotides encoding thereof and methods of making and using these domains and polynucleotides are useful in controlling the half-life of therapeutic molecules for patients.

What is claimed: 
     
       1. An isolated non-natural albumin binding domain, comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 21-34. 
     
     
       2. The isolated albumin binding domain of  claim 1 , further comprising an extension of 5 amino acids at its N-terminus. 
     
     
       3. The isolated albumin binding domain of  claim 2 , wherein the extension of 5 amino acids comprises an amino acid sequence of SEQ ID NOs: 42, 43 or 45-55. 
     
     
       4. The isolated albumin binding domain of  claim 2 , wherein the extension of 5 amino acids comprises an amino acid sequence of SEQ ID NO: 43. 
     
     
       5. The isolated albumin binding domain of  claim 2 , comprising the amino acid sequence of SEQ ID NO:44. 
     
     
       6. A fusion protein comprising an albumin binding domain of  claim 1  and a bioactive agent selected from the group consisting of proteins, antibodies, peptides, nucleotides, and small molecule pharmaceuticals, wherein the bioactive agent specifically binds a target molecule. 
     
     
       7. The fusion protein of  claim 6 , wherein the bioactive agent is a protein scaffold comprising a consensus sequence of a fibronectin type III (FN3) repeat protein. 
     
     
       8. The fusion protein of  claim 7 , wherein the protein scaffold comprises amino acid residues 1-90 of SEQ ID NO: 39. 
     
     
       9. The fusion protein of  claim 7 , wherein the albumin binding protein and the bioactive agent are operably linked by a linker. 
     
     
       10. The fusion protein of  claim 9 , wherein the linker comprises a Gly-Ser linker. 
     
     
       11. The fusion protein of  claim 10 , wherein the linker comprises an amino acid sequence of SEQ ID NO: 40. 
     
     
       12. A pharmaceutical composition comprising the fusion protein of  claim 6  and at least one pharmaceutically acceptable carrier or diluent.